Novartis has exercised an option to in-license a recombinant human lubricin (rh-Lubricin) protein for ophthalmic indications worldwide outside Europe from Lubris LLC, a Boston-based biopharmaceutical company that developed the rh-Lubricin protein for treating dry eye symptoms.

This in-licensing deal expands Novartis’ ophthalmology and dry eye treatment portfolio, which includes artificial tear products Systane, Tears Naturale, and Genteal. The closing of the deal is subject to customary closing conditions including regulatory approvals. Financial and other terms of this transaction were not disclosed.

Source: Novartis